Information Provided By: 
Fly News Breaks for November 17, 2015
OPHT
Nov 17, 2015 | 07:01 EDT
Citi analyst Yigal Nochomovitz raised his price target for Ophthotech to $102 saying recent data points bolster his bullish thesis on Fovista. A recent survey of nearly 1,000 retinal specialists indicated that 64% of U.S. physicians would use Avastin in newly diagnosed wet macular degeneration, Nochomovitz tells investors in a research note. This is above the analyst's previous estimate of 50%. The survey suggests peak U.S. Fovista revenue of $2.5B, Nochomovitz points out. He keeps a Buy rating on Ophthotech.
News For OPHT From the Last 2 Days
There are no results for your query OPHT
